Table 2.
Patient demographics (n = 19)
| Patient Characteristics | |
|---|---|
| Age in years, median (range) | 70 (43-86) |
| ≥ 65 years, n (%) | 11 (57) |
| Female, n (%) | 1 (5) |
|
Rai stage at study entry, n (%) | |
| Intermediate Risk (I/II) | 3 (15) |
| High Risk (III/IV) | 16 (84) |
|
WHO Performance Status, n (%) | |
| 0 | 5 (26) |
| 1 | 14 (73) |
| 2 | 0 |
|
Organomegaly, n (%) | |
| Radiographic evidence of splenomegaly (>10 cm) | 11 (57) |
| Radiographic evidence of hepatomegaly (>12cm) | 3 (15) |
| Lymphadenopathy | 16 (84) |
|
Hematologic parameters, median (range) | |
| WBC (×103/μl) | 9.8 (2.3-211) |
| Hemoglobin (g/dL) | 10.3 (7.7-13.5) |
| Platelets (× 109/L) | 67 (20-156) |
| LDH (μg/mL), median (range) | 207 (93-526) |
| Unmutated IGHV, n (%) | 16 (84) |
|
Interphase cytogenetic abnormalities, n (%) | |
| n (%) with del(13q14.3) | 7 (36) |
| n (%) with del(11q22.3) | 4 (21) |
| n (%) with del (17p13.1) | 9 (47) |
| n (%) with Trisomy 12 | 3 (15) |
|
Treatment history, n (%) | |
| Prior therapies, median (range) | 3 (1-8) |
| n (%) alkylator-refractory | 16 (84) |
| n (%) fludarabine-refractory | 13 (68) |
| Weeks since most recent therapy, median (range) | 4 (2-42) |
| Refractory to most recent therapy, n (%) | 9 (47) |
| Refractory to ibrutinib, n (%) | 2 (10) |